321 related articles for article (PubMed ID: 19723143)
61. The Expression Status and Prognostic Value of Cancer Stem Cell Biomarker CD133 in Cutaneous Squamous Cell Carcinoma.
Xu R; Cai MY; Luo RZ; Tian X; Han JD; Chen MK
JAMA Dermatol; 2016 Mar; 152(3):305-11. PubMed ID: 26560495
[TBL] [Abstract][Full Text] [Related]
62. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.
Thon N; Damianoff K; Hegermann J; Grau S; Krebs B; Schnell O; Tonn JC; Goldbrunner R
Mol Cell Neurosci; 2010 Jan; 43(1):51-9. PubMed ID: 18761091
[TBL] [Abstract][Full Text] [Related]
63. [Association of CD133 expression and sensitivity of rectal cancer to preoperative radiotherapy].
Qiu JM; Yang GG; Lu XJ; Wang X; Shen Z; Zhang XF
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Oct; 15(10):1066-9. PubMed ID: 23099908
[TBL] [Abstract][Full Text] [Related]
64. CD133 expression predicts for non-response to chemotherapy in colorectal cancer.
Ong CW; Kim LG; Kong HH; Low LY; Iacopetta B; Soong R; Salto-Tellez M
Mod Pathol; 2010 Mar; 23(3):450-7. PubMed ID: 20081809
[TBL] [Abstract][Full Text] [Related]
65. Proteomic profiling of tumor-initiating cells in HT-29 human colorectal cancer cells.
Lee HN; Park SH; Lee EK; Bernardo R; Kim CW
Biochem Biophys Res Commun; 2012 Oct; 427(1):171-7. PubMed ID: 22995320
[TBL] [Abstract][Full Text] [Related]
66. Prognostic impact of CD133 expression in gastric carcinoma.
Ishigami S; Ueno S; Arigami T; Uchikado Y; Setoyama T; Arima H; Kita Y; Kurahara H; Okumura H; Matsumoto M; Kijima Y; Natsugoe S
Anticancer Res; 2010 Jun; 30(6):2453-7. PubMed ID: 20651407
[TBL] [Abstract][Full Text] [Related]
67. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma.
Chen S; Hou JH; Feng XY; Zhang XS; Zhou ZW; Yun JP; Chen YB; Cai MY
J Surg Oncol; 2013 Jun; 107(8):799-806. PubMed ID: 23609373
[TBL] [Abstract][Full Text] [Related]
68. Isolation, characterization and mobilization of prostate cancer tissue derived CD133+ MDR1+ cells.
Rentala S; Mangamoori LN
J Stem Cells; 2010; 5(2):75-81. PubMed ID: 22049617
[TBL] [Abstract][Full Text] [Related]
69. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
Wu X; Wu F; Xu D; Zhang T
J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
[TBL] [Abstract][Full Text] [Related]
70. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
Lönnroth C; Andersson M; Nordgren S; Lundholm K
Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364
[TBL] [Abstract][Full Text] [Related]
71. CD133: molecule of the moment.
Mizrak D; Brittan M; Alison M
J Pathol; 2008 Jan; 214(1):3-9. PubMed ID: 18067118
[TBL] [Abstract][Full Text] [Related]
72. Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?
Neuzil J; Stantic M; Zobalova R; Chladova J; Wang X; Prochazka L; Dong L; Andera L; Ralph SJ
Biochem Biophys Res Commun; 2007 Apr; 355(4):855-9. PubMed ID: 17307142
[TBL] [Abstract][Full Text] [Related]
73. Significance of CD133 expression in esophageal squamous cell carcinoma.
Okamoto H; Fujishima F; Nakamura Y; Zuguchi M; Ozawa Y; Takahashi Y; Miyata G; Kamei T; Nakano T; Taniyama Y; Teshima J; Watanabe M; Sato A; Ohuchi N; Sasano H
World J Surg Oncol; 2013 Mar; 11():51. PubMed ID: 23448401
[TBL] [Abstract][Full Text] [Related]
74. [Experimental investigation of CD133 as a putative marker of tumor-initiating cell in laryngeal carcinoma].
Wei XD; Zhou L; Cheng L; Tian J
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2006 Dec; 41(12):940-4. PubMed ID: 17345710
[TBL] [Abstract][Full Text] [Related]
75. Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer.
Nagata T; Sakakura C; Komiyama S; Miyashita A; Nishio M; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Ikoma H; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Otsuji E
Anticancer Res; 2011 Feb; 31(2):495-500. PubMed ID: 21378329
[TBL] [Abstract][Full Text] [Related]
76. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma.
Hou YC; Chao YJ; Tung HL; Wang HC; Shan YS
Cancer; 2014 Sep; 120(17):2766-77. PubMed ID: 24839953
[TBL] [Abstract][Full Text] [Related]
77. Cell cycle analysis of the CD133(+) and CD133(-) cells isolated from human colorectal cancer.
Gharagozloo M; Mirzaei HR; Bagherpour B; Rezaei A; Kalantari H; Sanei MH; Hosseini M; Mohajeri G; Tabatabai A; Hashemi M
J Cancer Res Ther; 2012; 8(3):399-403. PubMed ID: 23174722
[TBL] [Abstract][Full Text] [Related]
78. Clinicopathological Significance of CD133 and ALDH1 Cancer Stem Cell Marker Expression in Invasive Ductal Breast Carcinoma.
Mansour SF; Atwa MM
Asian Pac J Cancer Prev; 2015; 16(17):7491-6. PubMed ID: 26625750
[TBL] [Abstract][Full Text] [Related]
79. CD133 expression in rectal cancer after preoperative chemoradiotherapy.
Kojima M; Ishii G; Atsumi N; Nishizawa Y; Saito N; Ochiai A
Cancer Sci; 2010 Apr; 101(4):906-12. PubMed ID: 20219069
[TBL] [Abstract][Full Text] [Related]
80. Research progression of CD133 as a marker of cancer stem cells.
Zhang H; Li SY
Chin J Cancer; 2010 Mar; 29(3):243-7. PubMed ID: 20193104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
